PEG-rhG-CSF
Trials 35
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05970185 | Feb → Apr 2024 | — | Zhongnan Hospital | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05222009 | Jan → Nov 2022 | — | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 1 | NCT03206229 | Feb → Jun 2017 | — | Adello Biologics, LLC | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT04477616 | Jul 2021 → Oct 2022 | breast cancer | The First Affiliated Hospital with Nanjing Medical University | Completed | No outcome recorded |
| Phase 2 | NCT04547829 | Oct 2020 → Oct 2022 | childhood malignant neoplasm | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT04542356 | Aug 2018 → Jan 2021 | cervical cancer | Chongqing University Cancer Hospital | Completed | Met primary |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT06520163 | Aug 2024 → Aug 2026 overdue | non-Hodgkin lymphoma | The Affiliated People's Hospital of Ningbo University | Recruiting | No outcome recorded |
| Phase 3 | NCT04466137 | Oct 2020 → Jun 2021 | neoplasm | Xiamen Amoytop Biotech Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT02761460 | May 2016 → Apr 2018 | breast cancer | wang shusen | Unknown | No outcome recorded |
| Phase 415 trials | ||||||
| Phase 4 | NCT05409547 | Jun 2022 → Apr 2025 | hemopoietic proliferation | Ning Huang | Unknown | No outcome recorded |
| Phase 4 | NCT06026995 | Mar 2022 → Jan 2024 | lymphoma | Chongqing University Cancer Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04083079 | Aug 2019 → Aug 2021 | non-Hodgkin lymphoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04009941 | Aug 2019 → Jan 2020 | breast cancer, neutropenia | Peking University | Completed | No outcome recorded |
| Phase 4 | NCT03858166 | Dec 2017 → Dec 2020 | ovarian cancer | Shandong University | Terminated | No outcome recorded |
| Phase 4 | NCT03206684 | Aug 2017 → Jul 2018 | cervical cancer | Air Force Military Medical University, China | Unknown | No outcome recorded |
| Phase 4 | NCT02996617 | Nov 2016 → Nov 2018 | non-Hodgkin lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02944604 | Sep 2016 → Sep 2017 | breast cancer | Peking University | Completed | No outcome recorded |
| Phase 4 | NCT02905916 | Jun 2016 → Jun 2018 | bone neoplasm, breast cancer, female reproductive system neoplasm, lymphoma | Peking University | Unknown | No outcome recorded |
| Phase 4 | NCT02905942 | Dec 2015 → Dec 2018 | lymphoma | Peking University | Unknown | No outcome recorded |
| Phase 4 | NCT02953730 | Sep 2015 → Jun 2016 | acute lymphoblastic leukemia | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02805218 | Sep 2013 → Feb 2016 | lymphoma | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02805153 | Apr 2013 → Feb 2016 | breast cancer | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02805205 | Apr 2013 → Feb 2016 | breast cancer | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02805166 | Apr 2013 → Feb 2016 | cancer | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT05834751 | May 2023 → May 2025 | lymphoma | Ou Bai, MD/PHD | Unknown | No outcome recorded |
| — | NCT05536154 | Nov 2022 → Jun 2024 | plasma cell myeloma | The Affiliated People's Hospital of Ningbo University | Unknown | No outcome recorded |
| — | NCT05510089 | Sep 2022 → May 2024 | hematopoietic and lymphoid cell neoplasm | The Affiliated People's Hospital of Ningbo University | Unknown | No outcome recorded |
| — | NCT05531279 | Jun 2022 → Jun 2025 | aplastic anemia | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| — | NCT05156554 | Dec 2021 → Dec 2022 | lymphoma | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT04500886 | Aug 2020 → Aug 2021 | hemophagocytic syndrome | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| — | NCT04497701 | Aug 2020 → Aug 2021 | leukemia, lymphoma | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| — | NCT04239001 | Feb → Dec 2020 | pancreatic neoplasm | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| — | NCT03870412 | Feb 2019 → Mar 2021 | adult lymphoma | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| — | NCT04497688 | Jan 2019 → Sep 2020 | non-Hodgkin lymphoma | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| — | NCT03776604 | Dec 2018 → Dec 2019 | small cell lung carcinoma | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT02005458 Comparator | Dec 2013 → Mar 2017 | breast cancer, non-small cell lung carcinoma | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT04554056 Comparator | Sep 2020 → Aug 2022 | female breast carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03731442 Background | Nov 2018 → Oct 2022 overdue | esophageal cancer | Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
Press releases naming this drug 42 releases
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 39 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-rhG-CSF | “Patients with NSCLC who received 1-4 chemotherapy cycles of docetaxel plus carboplatin were randomized 1:1:1 to receive telpegfilgrastim 2 mg, 33 µg/kg or control drug (rhG-CSF...” PMID 40098083 ↗ Mar 202537“Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) is rhG-CSF chemically modified by a single methoxy polyethylene glycol group; it is able to...” NCT02996617 ↗ “Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) can be used in pediatric patients.” PMID 37183837 ↗ May 2023 “6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection” NCT04477616 ↗ |
| Known as | Jinyouli | “Jin Youli(PEG-rhG-CSF):From the first cycle of chemotherapy, Jin Youli(PEG-rhG-CSF) was injected subcutaneously 24-72 hours after the end of chemotherapy, 6 mg was given to...” NCT03870412 ↗5“Patients received subcutaneous injection of PEG-rhG-CSF(Jinyouli®) 48 hours after the end of chemotherapy, 6mg for patients with body weight≥45kg and 3mg for patients with body...” NCT04497688 ↗ “A Single-center, Open-label, Controlled Clinical Study to Evaluate the Efficacy and Safety of Jinyouli®(PEG-rhG-CSF) for the Recovery of Neutropenia After Chemotherapy in...” NCT04500886 ↗ “Jin Youli(PEG-rhG-CSF): jinyouli injection was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period” NCT04239001 ↗ “Patients received a single dose of 100 ug/kg of PEG-rhG-CSF（Jinyouli®）, on the basis of actual body weight.” NCT04497701 ↗ “Jin Youli(PEG-rhG-CSF): The dose is determined according to the patient's weight.” NCT03776604 ↗ |
| Known as | mecapegfilgrastim | “polyethylene glycol-conjugated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF; mecapegfilgrastim) has been developed.” PMID 41510127 ↗ Dec 2025 |
| Known as | Neulasta | “Neulasta®, (PEG-rhG-CSF) Amgen, Thousand Oaks, CA” NCT03206229 ↗ |
| Known as | PEG-rhG-CSF injection | “PEG-rhG-CSF injection” NCT04554056 ↗ |
| Known as | pegfilgrastim | “patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy.” NCT02805153 ↗1“6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection” NCT04477616 ↗ |
| Known as | PEGylated Recombinant Human Granulocyte Stimulating Factor | “The purpose of the trail is to study the pharmacokinetics of Pegylated Recombinant Human Granulocyte Stimulating Factor（PEG-rhG-CSF） in Children and Adolescents” NCT02953730 ↗1“Jinyouli (PEGylated Recombinant Human Granulocyte Stimulating Factor, PEG-rhG-CSF)” NCT03776604 ↗ |
| Known as | Pegylated recombinant human granulocyte-colony stimulating factor | “Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) is rhG-CSF chemically modified by a single methoxy polyethylene glycol group; it is able to...” NCT02996617 ↗3“Pegylated recombinant human granulocyte-colony stimulating factor(PEG-rhG-CSF) is a first class national new drug developed by domestic pharmaceutical companies.” NCT02761460 ↗ “pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF)” NCT05409547 ↗ “PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)” NCT02944604 ↗ |
| Known as | pegylated rhG-CSF | “Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle” NCT02996617 ↗ |
| Known as | Xinruibai | “Patients with NSCLC who received 1-4 chemotherapy cycles of docetaxel plus carboplatin were randomized 1:1:1 to receive telpegfilgrastim 2 mg, 33 µg/kg or control drug (rhG-CSF...” PMID 40098083 ↗ Mar 2025 |
| Modality | Protein / enzyme biologic | “Pegylated recombinant human granulocyte-colony stimulating factor” NCT02761460 ↗ |
| Route | Subcutaneous | “100μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle” NCT02005458 ↗ |